Welcome to the News Room

In a world of global investment flows, securing a larger portion of the $150 billion invested per year by the research-based biopharmaceutical industry is anyone’s game. The 2017 results of the annual Biopharmaceutical Competitiveness & Investment (BCI) Survey, previewed at the International BIO Convention in San Diego in June, reveal that biopharmaceutical competitiveness turns on the policy conditions that countries decide to put in place.

A new blog post by Prof Meir Pugatch on PhRMA’s The Catalyst discusses these results and ...

Professor Meir Pugatch and Dr. David Torstensson are speaking today at the BIO international convention held in San Diego, CA. Sponsored by the Biotechnology Innovation Organization, the annual convention hosts more than 16,000 attendees from over 70 countries.

Yesterday Professor Pugatch participated in a high level discussion within the What in the World Matters? The Challenge of Spurring Innovation in Global Markets panel, which focused on the relatively slow uptake of biotech innovation in economies outside the US, and ...

Pugatch Consilium’s Biopharmaceutical Competitiveness & Investment Survey – known as the BCI – gained much attention when presented by Taiwan’s Vice-President, Chien-Jen Chen in his opening remarks at the BioBusiness Asia Conference which took place last week in Taipei.

VP Chen discussed the growth and development of Taiwan’s biotech industry, the challenges that still remain, and the new governmental policies in six areas of priorities in the biomedical industry, including increased efforts to harmonize the IP and legislative environments with international ...